GlassScriptPhysician profile
Toheed Jan Kamal
NPI 1174517536
$5,805.61
in general payments reported to CMS, 2019-2025
40 companies · $604 in 2025
The $604 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,063 · 2020: $1,026 · 2021: $1,401 · 2022: $651 · 2023: $631 · 2024: $428 · 2025: $604.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,664.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,664.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,277.91 | 2019-2025 | Ozempic, Rybelsus |
| Sanofi-Aventis U.S. LLC | $867.36 | 2019-2024 | |
| Corcept Therapeutics | $606.02 | 2019-2025 | Korlym |
| Astrazeneca Pharmaceuticals LP | $423.86 | 2019-2022 | |
| Medtronic, INC. | $294.84 | 2021-2025 | Minimed 780g |
| Bayer Healthcare Pharmaceuticals INC. | $230.15 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $217.66 | 2019-2025 | Jardiance |
| Amgen INC. | $197.68 | 2020-2025 | Repatha, Tepezza |
| Esperion Therapeutics, INC. | $174.60 | 2020-2024 | Nexletol |
| Genzyme Corporation | $162.00 | 2019-2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $115.76 | 2019-2022 | |
| Amarin Pharma, INC. | $111.60 | 2019-2021 | |
| Xeris Pharmaceuticals, INC. | $109.15 | 2022-2025 | Gvoke Hypopen |
| Abbott Laboratories | $106.87 | 2020-2024 | Aveir |
| Janssen Pharmaceuticals, INC | $95.93 | 2019-2021 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $84.93 | 2023-2025 | Leqvio |
| Lilly USA, LLC | $82.95 | 2020-2023 | Jardiance |
| Beta Bionics, INC. | $80.77 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Merck Sharp & Dohme LLC | $66.59 | 2019-2021 | |
| Dexcom, INC. | $48.83 | 2022-2023 | Dexcom G6 Transmitter |
| Lantheus Medical Imaging, INC. | $43.44 | 2020-2021 | |
| Ultragenyx Pharmaceutical INC. | $42.97 | 2021-2023 | |
| Glaxosmithkline, LLC. | $36.64 | 2025 | Shingrix, Arexvy |
| Impulse Dynamics (USA) INC. | $33.90 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $26.68 | 2021 | |
| Atricure, INC. | $25.56 | 2025 | Atriclip Laa Exclusion System |
| Arbor Pharmaceuticals, INC. | $23.58 | 2019-2020 | |
| Kyowa Kirin, INC. | $20.93 | 2025 | |
| Amryt Pharma Holdings LTD | $18.79 | 2023 | Mycapssa |
| Abbvie INC. | $18.72 | 2024 | |
| Mannkind Corporation | $18.59 | 2025 | |
| Shire North American Group INC | $17.88 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $17.61 | 2024 | Arcalyst |
| Daiichi Sankyo INC. | $17.05 | 2022 | |
| Averitas Pharma INC. | $16.29 | 2025 | Qutenza |
| Horizon Therapeutics Plc | $16.00 | 2022 | |
| Ibsa Pharma INC. | $14.52 | 2023 | Tirosint, Licart |
| Amneal Pharmaceuticals LLC | $14.00 | 2021 | |
| Pfizer INC. | $13.76 | 2019 | |
| Cvrx, INC. | $13.24 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Toheed Kamal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.